X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat cold, immune-excluded tumors, which are resistant to existing immunotherapy.
Lead Product(s): IMGS-001
Therapeutic Area: Oncology Product Name: IMGS-001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
The funding will be used to support the Phase 1a/1b clinical trial of ImmunoGenesis' lead candidate, IMGS-001, a dual-specific PD-L1/PD-L2 antibody designed to treat immune-excluded tumors, which are resistant to existing immunotherapy.
Lead Product(s): IMGS-001
Therapeutic Area: Oncology Product Name: IMGS-001
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cancer Focus Fund
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Funding June 27, 2023
Details:
IMGS-001, a PD-L1/PD-L2 dual-specific inhibitor with cytotoxic effector function. As first molecule to target PD-L2 in addition to PD-L1, has to shut down entire PD-1 pathway, providing superior blockade compared to other PD-1 or PD-L1 inhibitors.
Lead Product(s): IMGS-001
Therapeutic Area: Oncology Product Name: IMGS-001
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
As the first molecule to target PD-L2 in addition to PD-L1, IMGS-001 has the potential to shut down the entire PD-1 pathway, potentially providing superior blockade compared to other PD-1 or PD-L1 inhibitors.
Lead Product(s): IMGS-001
Therapeutic Area: Oncology Product Name: IMGS-001
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
IMGS-001 dual-specific PD‑L1/PD‑L2 antibody designed with effector function to kill the immunosuppressive cells in the tumor microenvironment, re-envisions the starting point for cold tumor treatment.
Lead Product(s): IMGS-001
Therapeutic Area: Oncology Product Name: IMGS-001
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2021
Details:
Funding will support pre-clinical and clinical development through a Phase 1A/1B trial of IMGS-001, a novel Checkpoint Inhibitor Drug Candidate.
Lead Product(s): IMGS-001
Therapeutic Area: Oncology Product Name: IMGS-001
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cancer Prevention and Research Institute of Texas
Deal Size: $15.5 million Upfront Cash: Undisclosed
Deal Type: Funding August 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
